If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A UK-based SME has developed novel fluorescent molecular imaging technology for biological and medical science research. They are offering their conjugated polymer nanoparticles to companies that are using fluorescent probes in their products, services or workflows to reach new markets and further develop their technology. It is envisaged that the partnership will take the form of a technical cooperation agreement.
The use of fluorescent probes is an essential part of biological science research and provides a vital tool for medical research. They are used to detect and monitor molecules of interest within cells and tissues among other applications. However, the technology currently used has not developed much since the 1980's and has several flaws that limit effectiveness. This includes limited brightness, photobleaching, and poor stability of current fluorescent probes, which restricts sensitivity.
A UK-based SME has developed a novel fluorescent molecular imaging probe technology that overcomes these limitations. They have developed conjugated polymer nanoparticles containing a semiconductor light emitting polymer core, encapsulated within a surfactant. These particles are brighter and more stable than currently used technology such as fluorophores and quantum dots, making them more sensitive. They are also non-toxic so can be used in live cell and tissue imaging as well as in in vivo experiments. These particles can also incorporate a magnetic core enabling additional functions such as sample purification. The particles can be used in existing methodologies (fluorescent microscopy, flow cytometry, immunohisto/cytochemistry, Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Tests, lateral flow diagnostics etc.) with no changes to protocols needed.
The UK-based SME is looking to further develop this technology and enter new markets. They are therefore offering their conjugated polymer nanoparticles to companies that are using or plan to use existing fluorescent imaging probes in their products or services and workflows. The SME would like feedback from partner companies on the use of their nanoparticles in products and workflows so they can further adapt and develop the technologies to add to their portfolio. It is envisaged that the partnership will take the form of a technical cooperation but other partnerships will be considered depending on individual circumstances.
The UK-based SME's novel conjugated polymer nanoparticle imaging probes have the following advantages:
1. High degree of photostability preventing loss of signal due to photobleaching.
2. Highly specific targeting.
3. Non-toxic enabling normal cell and tissue function to be studied.
4. Compatible with current molecular detection systems (fluorescent microscopy, flow cytometry, immunohisto/cytochemistry, ELISA, Rapid Diagnostic Tests, lateral flow diagnostics etc.)
5. Can be used in vivo and in vitro with no changes to existing, established protocols.
6. Magnetic core capability enables modal imaging and magnetic sample purification.
7. 1400x brighter than existing alexa fluorophores, 200x brighter than Quantum Dots.
8. Four wavelengths can be produced at scale with a further four wavelengths in development and will be available in 2019.
The first 4 wavelengths of particles are fully developed and can be produced at scale. A further 4 wavelengths will be added in early 2019. A wide variety of linking chemistries are possible with the particles and the company is open to collaborations to develop these further.
The UK-based SME is looking to partner with companies who are using, or are looking to use, fluorescent imaging probes in their products or systems. The UK-based SME will offer their unique conjugated polymer nanoparticles to partner companies to incorporate into their systems, products and workflows. They would expect feedback from the partner companies in relation to the performance of the conjugated polymer nanoparticles in their products and workflows in order to inform further development of the existing conjugated polymer nanoparticles and introduction of new product lines. It is envisaged that the partnership will take the form of a technical cooperation agreement although other partnerships will be considered dependent on circumstances.